Exelixis, Bristol-Myers Squibb Oncology Deal Yields First Targets | GenomeWeb

NEW YORK, Dec. 13 - Exelixis and Bristol-Myers Squibb said they have identified and selected the first small molecule cancer targets to result from a broad oncology collaboration announced five months ago.

Exelixis, which uses invertebrate and vertebrate gene knockout models to study how certain genes interact in cancer cells to identify particular genes that help suppress tumor growth, said it had identified ways that tumor cells “evade normal growth control mechanisms.”

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.